Enzon Pharmaceuticals (ENZN)
OTHER OTC:ENZN

Enzon Pharmaceuticals (ENZN) Income Statement

83 Followers

Enzon Pharmaceuticals Income Statement

Last quarter (Q ), Enzon Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Enzon Pharmaceuticals's net income was $-211.00K. See Enzon Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
--$ 26.00K$ 701.00K$ 52.00K$ 207.00K
Cost of Revenue
------
Gross Profit
--$ 26.00K$ 701.00K--
Operating Expense
$ 1.08M$ 1.04M$ 1.06M$ 1.17M$ 1.36M$ 1.18M
Operating Income
$ -1.08M$ -1.04M$ -1.03M$ -469.00K$ -1.30M$ -973.00K
Net Non Operating Interest Income Expense
------
Other Income Expense
--$ -646.00K$ -7.00K$ 1.00K-
Pretax Income
$ 1.38M$ 1.22M$ -386.00K$ -462.00K$ -1.30M$ -973.00K
Tax Provision
$ -120.00K$ -156.00K$ -200.00K$ 7.00K$ 7.00K$ 6.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 221.00K$ 98.00K$ -1.46M$ -2.49M$ -1.77M$ -979.00K
Basic EPS
--$ -0.02$ -0.03$ -0.03$ -0.02
Diluted EPS
--$ -0.02$ -0.03$ -0.03$ -0.02
Basic Average Shares
$ 371.00M$ 74.22M$ 74.22K$ 74.22K$ 51.10M$ 44.22M
Diluted Average Shares
$ 371.00M$ 74.22M$ 74.22K$ 74.22K$ 51.10M$ 44.22M
Dividend Per Share
----$ 0.00$ 0.12
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 653.00K$ 1.04M$ 1.06M$ 1.17M$ 1.36M$ 1.18M
Net Income From Continuing And Discontinued Operation
$ 1.50M$ 1.37M$ -186.00K$ -469.00K$ -1.31M$ -979.00K
Normalized Income
$ 499.28K$ 1.06M$ -586.00K-$ -1.31M$ -979.00K
Interest Expense
------
EBIT
$ 953.00K$ 1.22M$ -386.00K$ -462.00K$ -1.30M$ -973.00K
EBITDA
$ 321.00K$ 1.22M$ -386.00K$ -462.00K$ -1.30M$ -973.00K
Currency in USD

Enzon Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis